Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial

被引：2
|
作者：
Marandino, L. [1 ]
Raggi, D. [1 ]
Giannatempo, P. [1 ]
Calareso, G. [2 ]
Alessi, A. [3 ]
Colecchia, M. [4 ]
Madison, R. [5 ]
Ross, J. S. [6 ]
Necchi, A. [1 ]
机构：
[1] Ist Nazl Tumori Milano Fdn IRCCS, Dept Med Oncol, Milan, Italy
[2] Ist Nazl Tumori Milano, Fdn IRCCS, Radiol, Milan, Italy
[3] Ist Nazl Tumori Milano Fdn IRCCS, Nucl Med, Milan, Italy
[4] Ist Nazl Tumori Milano Fdn IRCCS, Pathol, Milan, Italy
[5] Fdn Med Inc, Clin Bioinformat Operat, Cambridge, MA USA
[6] Fdn Med Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
773P
引用
收藏
页码：S595 / S595
页数：1
相关论文
共 50 条
  • [21] Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
    Apolo, Andrea B.
    Nadal, Rosa
    Tomita, Yusuke
    Davarpanah, Nicole N.
    Cordes, Lisa M.
    Steinberg, Seth M.
    Cao, Liang
    Parnes, Howard L.
    Costello, Rene
    Merino, Maria J.
    Folio, Les R.
    Lindenberg, Liza
    Raffeld, Mark
    Lin, Jeffrey
    Lee, Min-Jung
    Lee, Sunmin
    Alarcon, Sylvia V.
    Yuno, Akira
    Dawson, Nancy A.
    Allette, Kimaada
    Roy, Arpita
    De Silva, Dinuka
    Lee, Molly M.
    Sissung, Tristan M.
    Figg, William D.
    Agarwal, Piyush K.
    Wright, John J.
    Ning, Yangmin M.
    Gulley, James L.
    Dahut, William L.
    Bottaro, Donald P.
    Trepel, Jane B.
    LANCET ONCOLOGY, 2020, 21 (08): : 1099 - 1109
  • [22] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Cao, Yanshuo
    Lu, Ming
    Sun, Yu
    Gong, Jifang
    Li, Jie
    Lu, Zhihao
    Li, Jian
    Zhang, Xiaotian
    Li, Yan
    Peng, Zhi
    Zhou, Jun
    Wang, Xicheng
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
  • [23] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Yanshuo Cao
    Ming Lu
    Yu Sun
    Jifang Gong
    Jie Li
    Zhihao Lu
    Jian Li
    Xiaotian Zhang
    Yan Li
    Zhi Peng
    Jun Zhou
    Xicheng Wang
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
  • [24] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
    Guo, Honghai
    Ding, Ping'an
    Sun, Chenyu
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Lowe, Scott
    Bentley, Rachel
    Li, Yaru
    Zhang, Zhidong
    Wang, Dong
    Li, Yong
    Zhao, Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial
    Wei, Zhigong
    Zhu, Yuchun
    Cai, Lei
    Peng, Xingchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [27] Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
    Chen, Xiaofeng
    Wu, Xiaofeng
    Wu, Hao
    Gu, Yanhong
    Shao, Yang
    Shao, Qianwen
    Zhu, Feipeng
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Zhao, Fengjiao
    Mao, Weidong
    Sun, Jing
    Wang, Jian
    Han, Gaohua
    Li, Changxian
    Xia, Yongxiang
    Seesaha, Poshita Kumari
    Zhu, Dongqin
    Li, Huajun
    Zhang, Junling
    Wang, Guoqiang
    Wang, Xuehao
    Li, Xiangcheng
    Shu, Yongqian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [28] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.
    Guo, Honghai
    Ding, Ping'an
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Zhang, Ze
    Zheng, Tao
    Zhang, Zhidong
    Wang, Dong
    Tan, Bibo
    Zhao, Xuefeng
    Li, Yong
    Zhao, Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091
  • [29] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
    Choueiri, Toni K.
    McDermott, David F.
    Merchan, Jaime
    Bauer, Todd M.
    Figlin, Robert
    Heath, Elisabeth, I
    Michaelson, M. Dror
    Arrowsmith, Edward
    D'Souza, Anishka
    Zhao, Song
    Roy, Ananya
    Perini, Rodolfo
    Vickery, Donna
    Tykodi, Scott S.
    LANCET ONCOLOGY, 2023, 24 (05): : 553 - 562
  • [30] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
12345